ClinicalTrials.gg
CompletedNCT02718326PANORAMAUpdated Jul 30, 2020Results posted

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

A Phase 3 interventional study of Intravitreal aflibercept injection [IAI] and Sham in Nonproliferative Diabetic Retinopathy, sponsored by Regeneron Pharmaceuticals. Completed at 89 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-30.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing aflibercept in Diabetic Retinopathy — 2 open to participants now, 4 under way, none of them phase 3. aflibercept · Diabetic Retinopathy.

Enrollment
2nd of 21
402 · median 38
Started
2016
with 5 others
Phase 3
3 of 21
none open now
Registered
8th of 21
by date
Lead sponsor
2 of 21
Regeneron Pharmaceuticals

Among the 21 studies testing aflibercept in Diabetic Retinopathy, this one is the 2nd largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 3, and was the 8th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 21 studies testing aflibercept in Diabetic Retinopathy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing aflibercept in Diabetic Retinopathy, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).

The secondary objectives of the study are:

  • To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR
  • To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME
  • To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR
03

Conditions studied

  • Nonproliferative Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe nonproliferative diabetic retinopathy (NPDR) [(diabetic retinopathy severity scale (DRSS) levels 47 or 53)], confirmed by the central reading center, in whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months per the investigator
  2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)

Key Exclusion Criteria:

  1. Presence of diabetic macular edema (DME) threatening the center of the macula in the study eye
  2. Evidence of retinal neovascularization on clinical examination or Fluorescein Angiography (FA)
  3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye
  4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or intravitreal (IVT) anti-VEGF treatment in the study eye
  5. Any prior intraocular injection in the study eye
  6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye

Note: Other inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    Dosing regimen 1

    Participants will receive IVT aflibercept dosing regimen 1

    Drug: Intravitreal aflibercept injection [IAI]

  • Experimental
    Dosing regimen 2

    Participants will receive IVT aflibercept dosing regimen 2

    Drug: Intravitreal aflibercept injection [IAI]

  • Sham comparator
    Dosing regimen 3

    Participants will receive matching sham injections

    Drug: Sham

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups

    The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24 from baseline.

    Time frame: At Week 24

  2. Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

    The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 52 from baseline.

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52

    Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle).

    Time frame: At Week 52

  2. Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52

    The percentage of participants who developed CI-DME at week 52 were reported.

    Time frame: At Week 52

  3. Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52

    Vision-threatening complication (VTC) is defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle). Vision Threatening Complications include PDR/ASNV identified by investigators and Diabetic Retinopathy Scale Score (DRSS) \>61.

    Time frame: Baseline through week 52 (day 365)

  4. Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52

    Time to develop Central Involved-Diabetic Macular Edema (CI-DME) through week 52 reported.

    Time frame: Baseline through week 52 (day 365)

  5. Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52

    The percentage of participants who received panretinal photocoagulation (PRP), inclusive of participants undergoing vitrectomy with endolaser, at week 52 were reported.

    Time frame: At Week 52

  6. Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

    The area under the curve (AUC) is the area under the best corrected visual acuity (BCVA) versus time curve from baseline to week 52. Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

    Time frame: At week 52

07

Results

Posted Nov 21, 2019

Participant flow

Recruitment for this study was conducted in the following countries between 29 Mar 2016 and 07 Aug 2017: Germany, Hungary, Japan, the United Kingdom, and the United States. A total of 759 participants were screened.

Participant flow — Overall Study
MilestoneSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Started133135134
Completed week 52109122124
Completed97111112
Not completed362422
Withdrew: Adverse event490
Withdrew: Death812
Withdrew: Withdrawal by subject496
Withdrew: Lost to follow-up18514
Withdrew: Protocol deviation100
Withdrew: Pregnancy100

Outcome measures

PrimaryPercentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups

The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24 from baseline.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups
Percentage of participantsSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8IAI 2 mg Groups Combined (2Q16 & 2Q8)
Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups6.061.555.258.4
Statistical analysis
  • Sham Treatment vs IAI 2 mg Groups Combined (2Q16 & 2Q8) · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 52.3 · 95% CI 45.2 to 59.5
PrimaryPercentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline

The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 52 from baseline.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline
Percentage of participantsSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline15.065.279.9
Statistical analysis
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q16 · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 50.1 · 95% CI 40.1 to 60.1
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q8 · Cochran-Mantel-Haenszel · p = < 0.0001 · Percentage difference: 64.8 · 95% CI 55.8 to 73.9
SecondaryPercentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52

Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle).

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52
Percentage of participantsSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 5220.33.73.0
Statistical analysis
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q8 · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: -17.3 · 95% CI -24.7 to -9.9
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q16 · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: -16.6 · 95% CI -24.2 to -9.1
SecondaryPercentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52

The percentage of participants who developed CI-DME at week 52 were reported.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52
Percentage of participantsSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 5225.66.78.2
Statistical analysis
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q8 · Cochran-Mantel-Haenszel · p = = 0.0002 · Percentage difference: -17.3 · 95% CI -26.2 to -8.5
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q16 · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: -18.9 · 95% CI -27.5 to -10.4
SecondaryTime to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52

Vision-threatening complication (VTC) is defined as the composite outcome of proliferative diabetic retinopathy (PDR) (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris \[at least 2 cumulative clock hours\], and/or definitive neovascularization of the iridocorneal angle). Vision Threatening Complications include PDR/ASNV identified by investigators and Diabetic Retinopathy Scale Score (DRSS) \>61.

Time frame:
Baseline through week 52 (day 365)
Reported as:
Median · Days
Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52
DaysSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52NA (371 to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52

Time to develop Central Involved-Diabetic Macular Edema (CI-DME) through week 52 reported.

Time frame:
Baseline through week 52 (day 365)
Reported as:
Median · Days
Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52
DaysSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52NA (333 to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52

The percentage of participants who received panretinal photocoagulation (PRP), inclusive of participants undergoing vitrectomy with endolaser, at week 52 were reported.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52
Percentage of participantsSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 526.80.70.7
Statistical analysis
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q8 · Cochran-Mantel-Haenszel · p = 0.0096 · Percentage difference: -6.0 · 95% CI -10.5 to -1.5
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q16 · Cochran-Mantel-Haenszel · p = 0.0089 · Percentage difference: -6.0 · 95% CI -10.5 to -1.6
SecondaryArea Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

The area under the curve (AUC) is the area under the best corrected visual acuity (BCVA) versus time curve from baseline to week 52. Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best).

Time frame:
At week 52
Reported as:
Mean · scores on a scale
Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
scores on a scaleSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8
Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 520.5 ± 3.011.7 ± 3.501.3 ± 3.49
Statistical analysis
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q8 · ANOVA · p = 0.0529 · Estimate for contrast: 0.80 · 95% CI -0.01 to 1.60
  • Sham Treatment vs Intravitreal Aflibercept Injection (IAI) 2Q16 · ANOVA · p = 0.0057 · Estimate for contrast: 1.14 · 95% CI 0.33 to 1.94

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to week 100 regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham Treatment8/133 (6%)38/133 (28.6%)104/133 (78.2%)
Intravitreal Aflibercept Injection (IAI) 2Q161/135 (0.7%)38/135 (28.1%)104/135 (77%)
Intravitreal Aflibercept Injection (IAI) 2Q83/134 (2.2%)47/134 (35.1%)106/134 (79.1%)
IAI 2 mg Groups Combined (2Q16 & 2Q8)4/269 (1.5%)85/269 (31.6%)210/269 (78.1%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8IAI 2 mg Groups Combined (2Q16 & 2Q8)
CellulitisInfections and infestations1/1332/1355/1347/269
Coronary artery diseaseCardiac disorders1/1335/1354/1349/269
OsteomyelitisInfections and infestations4/1331/1350/1341/269
Ischaemic strokeNervous system disorders3/1330/1350/1340/269
Cardiac failure congestiveCardiac disorders1/1332/1353/1345/269
PneumoniaInfections and infestations2/1333/1353/1346/269
SepsisInfections and infestations1/1330/1353/1343/269
DehydrationMetabolism and nutrition disorders1/1330/1353/1343/269
Acute kidney injuryRenal and urinary disorders2/1331/1353/1344/269
Visual acuity reduced Fellow EyeEye disorders1/1330/1353/1343/269
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8IAI 2 mg Groups Combined (2Q16 & 2Q8)
Diabetic retinal oedema Study EyeEye disorders43/13314/13519/13433/269
HypertensionVascular disorders25/13328/13520/13448/269
Conjunctival haemorrhage Study EyeEye disorders8/13318/13525/13443/269
Diabetic retinal oedema Fellow EyeEye disorders19/13317/13523/13440/269
Diabetic retinopathy Study EyeEye disorders22/1333/1355/1348/269
Urinary tract infectionInfections and infestations16/13312/13511/13423/269
NasopharyngitisInfections and infestations15/13311/13511/13422/269
Diabetes mellitusMetabolism and nutrition disorders13/13311/1358/13419/269
Vitreous floaters Study EyeEye disorders3/1337/13513/13420/269
Diabetic retinopathy Fellow EyeEye disorders12/13313/13510/13423/269

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received any study treatment as assigned at baseline (as randomized).

Age, Continuous
Age, Continuous(Years)Sham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8Total
Mean55.8 ± 10.3155.4 ± 11.1355.8 ± 10.1955.7 ± 10.53
Sex: Female, Male
Sex: Female, Male(Participants)Sham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8Total
Female646053177
Male697581225
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8Total
Hispanic or Latino749793264
Not Hispanic or Latino583741136
Unknown or Not Reported1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8Total
American Indian or Alaska Native1146
Asian412723
Native Hawaiian or Other Pacific Islander0112
Black or African American13161241
White10799104310
More than one race0112
Unknown or Not Reported85518
Baseline Diabetic Retinopathy Severity Score (DRSS)
Baseline Diabetic Retinopathy Severity Score (DRSS)(Participants)Sham TreatmentIntravitreal Aflibercept Injection (IAI) 2Q16Intravitreal Aflibercept Injection (IAI) 2Q8Total
Level 47 (Moderately Severe)99102101302
Level 53 (Severe)343333100
08

Study locations

89 sites
  • Regeneron Study Site
    Phoenix, Arizona 85020, United States
  • Regeneron Study Site
    Tucson, Arizona 85704, United States
  • Regeneron Study Site
    Arcadia, California 91007, United States
  • Regeneron Study Site
    Beverly Hills, California 90211, United States
  • Regeneron Study Site
    Encino, California 91436, United States
  • Regeneron Study Site
    Fullerton, California 92835, United States
  • Regeneron Study Site
    La Jolla, California 92093, United States
  • Regeneron Study Site
    Mountain View, California 94040, United States
  • Regeneron Study Site
    Oakland, California 94609, United States
  • Regeneron Study Site
    Oceanside, California 92056, United States
  • Regeneron Study Site
    Sacramento, California 95841, United States
  • Regeneron Study Site
    Colorado Springs, Colorado 80909, United States
  • Regeneron Study Site
    Golden, Colorado 80401, United States
  • Regeneron Study Site
    New London, Connecticut 06320, United States
  • Regeneron Study Site
    Altamonte Springs, Florida 32701, United States
  • Regeneron Study Site
    Deerfield Beach, Florida 33064, United States
  • Regeneron Study Site
    Fort Myers, Florida 33912, United States
  • Regeneron Study Site
    Lakeland, Florida 33805, United States
  • Regeneron Study Site
    Largo, Florida 33770, United States
  • Regeneron Study Site
    Melbourne, Florida 32901, United States
  • Regeneron Study Site
    Miami, Florida 33126, United States
  • Regeneron Study Site
    Miami, Florida 33143, United States
  • Regeneron Study Site
    Orlando, Florida 32806, United States
  • Regeneron Study Site
    Plantation, Florida 33324, United States
  • Regeneron Study Site
    Tallahassee, Florida 32308, United States
  • Regeneron Study Site
    Tampa, Florida 33612, United States
  • Regeneron Study Site
    Winter Haven, Florida 33880, United States
  • Regeneron Study Ssites
    Marietta, Georgia 30060, United States
  • Regeneron study Site
    Tucker, Georgia 30084, United States
  • Regeneron Study Site
    Chicago, Illinois 60612, United States
  • Regeneron Study Site
    Oak Forest, Illinois 60452, United States
  • Regeneron Study Site
    Indianapolis, Indiana 46290, United States
  • Regeneron Study Site
    New Albany, Indiana 47150, United States
  • Regeneron Study Site
    Lexington, Kentucky 40509, United States
  • Regeneron Study Site
    Baltimore, Maryland 21204, United States
  • Regeneron Study Siste
    Baltimore, Maryland 21209, United States
  • Regeneron Study Site
    Baltimore, Maryland 21287, United States
  • Regeneron Study Site
    Hagerstown, Maryland 21740, United States
  • Regeneron Study Site
    Boston, Massachusetts 02114, United States
  • Regeneron Study Site
    Henderson, Nevada 89052, United States
  • Regeneron Study Site
    Bloomfield, New Jersey 07003, United States
  • Regeneron Study Site
    Albuquerque, New Mexico 87109, United States
  • Regeneron Study Site
    Asheville, North Carolina 28803, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28210, United States
  • Regeneron Study Site
    Columbus, Ohio 43212, United States
  • Regeneron Study Site
    Oklahoma City, Oklahoma 73104, United States
  • Regeneron Study Site
    Medford, Oregon 97504, United States
  • Regeneron Study Site
    Kingston, Pennsylvania 18704, United States
  • Regeneron Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Regeneron Study Site
    Florence, South Carolina 29501, United States
  • Regeneron Study Site
    Ladson, South Carolina 29456, United States
  • Regeneron Study Site
    West Columbia, South Carolina 29169, United States
  • Regeneron Study Site
    Rapid City, South Dakota 57701, United States
  • Regeneron Study Site
    Chattanooga, Tennessee 37421, United States
  • Regeneron Study Site
    Germantown, Tennessee 38138, United States
  • Regeneron Study Site
    Nashville, Tennessee 37203, United States
  • Regeneron Study Site
    Nashville, Tennessee 37232, United States
  • Regeneron Study Site
    Abilene, Texas 79606, United States
  • Regeneron Study Site 1
    Austin, Texas 78705, United States
  • Regeneron Study Site 2
    Austin, Texas 78705, United States
  • Regeneron Study Site
    Dallas, Texas 75231, United States
  • Regeneron Study Site
    Harlingen, Texas 78559, United States
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    San Antonio, Texas 78240, United States
  • Regeneron Study Site
    The Woodlands, Texas 77384, United States
  • Regeneron Study Site
    Willow Park, Texas 76087, United States
  • Regeneron Study Site
    Salt Lake City, Utah 84132, United States
  • Regeneron Study Site
    Burlington, Vermont 05401, United States
  • Regeneron Study Site
    Fairfax, Virginia 22031, United States
  • Regeneron Study Site
    Spokane, Washington 99204, United States
  • Regeneron Study Site
    Morgantown, West Virginia 26506, United States
  • Regeneron Study Site
    Marburg, Hesse 35043, Germany
  • Regeneron Study Site
    Münster, North Rhine-Westphalia 48145, Germany
  • Regeneron Study Site
    Leipzig, Saxony 04103, Germany
  • Regeneron Study Site
    Szeged, Csongrad 6720, Hungary
  • Regeneron Study Site
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Regeneron Study Site
    Budapest, Pest 1062, Hungary
  • Regeneron Study Site
    Budapest, Pest 1106, Hungary
  • Regeneron Study Site
    Zalaegerszeg, Zala 8900, Hungary
  • Regeneron Study Site
    Asahikawa, Hokkaido 078-8510, Japan
  • Regeneron Study Site
    Amagasaki, Hyogo 660-8550, Japan
  • Regeneron Study Site
    Matsumoto, Nagano 390-8621, Japan
  • Regeneron Study Site
    Chiyoda, Tokyo 101-8309, Japan
  • Regeneron Study Site
    Kagoshima, 890-8520, Japan
  • Regeneron Study Site
    Nagasaki, 852-8501, Japan
  • Regeneron Study Site
    Arecibo, 00613, Puerto Rico
  • Regeneron Study Site
    San Juan, 00907, Puerto Rico
  • Regeneron Study Site
    Camberley, Surrey GU16 7UJ, United Kingdom
  • Regeneron Study Site
    London, EC1V 2PD, United Kingdom
09

References and documents

Publications

  • Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. PubMed 34351414 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2018, 28 months.

Results were first posted in Nov 2019, 1 year 3 months after primary completion.

Of 21 phase 3 interventional studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 41. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2016
First posted
Mar 24, 2016
StartActual
Mar 29, 2016
Primary completionActual
Aug 6, 2018
CompletionActual
Jul 16, 2019
Results first posted
Nov 21, 2019
Last update
Jul 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02718326
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Mar 29, 2016
Primary completion
Aug 6, 2018
Completion
Jul 16, 2019
Results posted
Nov 21, 2019
Last update
Jul 30, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion